{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T23:04:30Z","timestamp":1784761470278,"version":"3.55.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":72,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Ministry of Health","award":["Ricerca Corrente funds"],"award-info":[{"award-number":["Ricerca Corrente funds"]}]},{"name":"Ministry of Health","award":["Ricerca Corrente funds"],"award-info":[{"award-number":["Ricerca Corrente funds"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Breast Cancer"],"DOI":"10.1038\/s41523-026-00958-5","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T17:43:32Z","timestamp":1778607812000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond timing, toward precision: insights from CDK4\/6 inhibitor trials in metastatic breast cancer"],"prefix":"10.1038","volume":"12","author":[{"given":"Serena","family":"Di Cosimo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Apolone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"key":"958_CR1","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/s41586-024-08035-2","volume":"636","author":"GS Sonke","year":"2024","unstructured":"Sonke, G. S. et al. Early versus deferred use of CDK4\/6 inhibitors in advanced breast cancer. Nature 636, 474\u2013480 (2024).","journal-title":"Nature"},{"key":"958_CR2","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1056\/NEJMoa2502929","volume":"393","author":"FC Bidard","year":"2025","unstructured":"Bidard, F. C. et al. SERENA-6 study group. First-line camizestrant for emerging ESR1-mutated advanced breast cancer. N. Engl. J. Med. 393, 569\u2013580 (2025).","journal-title":"N. Engl. J. Med."},{"key":"958_CR3","unstructured":"Evaluation of anticancer medicinal products - Scientific guideline. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/concept-paper-revision-guideline-evaluation-anticancer-medicinal-products-appendices-revision-7_en.pdf, accessed November 6, 2025."},{"key":"958_CR4","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/s41571-025-01004-2","volume":"22","author":"S Paluch-Shimon","year":"2025","unstructured":"Paluch-Shimon, S. & Cardoso, F. The SONIA trial shows the power and challenges of academic research. Nat. Rev. Clin. Oncol. 22, 311\u2013312 (2025).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"958_CR5","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1038\/s41571-025-01066-2","volume":"22","author":"AJ Medford","year":"2025","unstructured":"Medford, A. J. & Wander, S. A. SERENA-6: dynamic ctDNA assessment and the future of precision cancer medicine. Nat. Rev. Clin. Oncol. 22, 804\u2013805 (2025).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"958_CR6","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.annonc.2023.08.011","volume":"11","author":"F Andr\u00e9","year":"2023","unstructured":"Andr\u00e9, F. et al. Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials. Ann. Oncol. 11, 1003\u20131014 (2023).","journal-title":"Ann. Oncol."},{"key":"958_CR7","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1158\/1078-0432.CCR-22-3573","volume":"30","author":"MP Goetz","year":"2024","unstructured":"Goetz, M. P. et al. Landscape of baseline and acquired genomic alterations in circulating tumor DNA with abemaciclib alone or with endocrine therapy in advanced breast cancer. Clin. Cancer Res. 30, 2233\u20132244 (2024).","journal-title":"Clin. Cancer Res."},{"key":"958_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-025-02095-6","volume":"27","author":"LV Ravani","year":"2025","unstructured":"Ravani, L. V. et al. Comparative efficacy of first- versus second-line CDK4\/6 inhibition in hormone receptor-positive, HER2-negative metastatic breast cancer. Breast Cancer Res. 27, 146 (2025).","journal-title":"Breast Cancer Res."},{"key":"958_CR9","doi-asserted-by":"publisher","first-page":"104125","DOI":"10.1016\/j.esmoop.2024.104125","volume":"10","author":"E Blondeaux","year":"2025","unstructured":"Blondeaux, E. et al. Factors associated with first-to-second-line attrition among patients with metastatic breast cancer in the real world. ESMO Open. 10, 104125 (2025).","journal-title":"ESMO Open."},{"key":"958_CR10","doi-asserted-by":"publisher","unstructured":"Wortelboer, N. et al. Overall Survival With First-Line vs Second-Line CDK4\/6 Inhibitor Use in Advanced Breast Cancer: A Randomized Clinical Trial. JAMA Oncology. Published online February 19, 2026. https:\/\/doi.org\/10.1001\/jamaoncol.2025.6585.","DOI":"10.1001\/jamaoncol.2025.6585"},{"key":"958_CR11","doi-asserted-by":"publisher","first-page":"3662","DOI":"10.1038\/s41591-025-03935-w","volume":"31","author":"EM Jogbloed","year":"2025","unstructured":"Jogbloed, E. M. et al. Early versus deferred use of CDK4\/6 inhibitors in advanced breast cancer: circulating tumor DNA analysis of a randomized phase 3 trial. Nat. Med. 31, 3662 (2025).","journal-title":"Nat. Med."},{"key":"958_CR12","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson, N. K. et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J. Natl. Cancer Inst. 85, 365\u2013376 (1993).","journal-title":"J. Natl. Cancer Inst."},{"key":"958_CR13","doi-asserted-by":"publisher","first-page":"dju244","DOI":"10.1093\/jnci\/dju244","volume":"106","author":"E Basch","year":"2014","unstructured":"Basch, E. et al. Development of the National Cancer Institute\u2019s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). J. Natl. Cancer Inst. 106, dju244 (2014).","journal-title":"J. Natl. Cancer Inst."},{"key":"958_CR14","unstructured":"https:\/\/qol.eortc.org\/questionnaire\/qlq-patsat-c33\/, accessed November 6, 2025."},{"key":"958_CR15","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1093\/jnci\/88.15.1039","volume":"88","author":"RD Gelber","year":"1996","unstructured":"Gelber, R. D. et al. A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of adjuvant radiation therapy and chemotherapy for resectable rectal cancer. J. Natl. Cancer Inst. 88, 1039\u20131045 (1996).","journal-title":"J. Natl. Cancer Inst."},{"key":"958_CR16","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ejca.2022.09.029","volume":"177","author":"M Huang","year":"2022","unstructured":"Huang, M. et al. Q-TWiST analysis of pembrolizumab combined with chemotherapy as first-line treatment of metastatic triple-negative breast cancer that expresses PD-L1. Eur. J. Cancer 177, 45\u201352 (2022).","journal-title":"Eur. J. Cancer"},{"key":"958_CR17","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1056\/NEJMoa2404625","volume":"391","author":"NC Turner","year":"2024","unstructured":"Turner, N. C. et al. Inavolisib-based therapy in PIK3CA-mutated advanced breast cancer. N. Engl. J. Med. 391, 1584\u20131596 (2024).","journal-title":"N. Engl. J. Med."}],"container-title":["npj Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41523-026-00958-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41523-026-00958-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41523-026-00958-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T22:35:52Z","timestamp":1784759752000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41523-026-00958-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["958"],"URL":"https:\/\/doi.org\/10.1038\/s41523-026-00958-5","relation":{},"ISSN":["2374-4677"],"issn-type":[{"value":"2374-4677","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,12]]},"assertion":[{"value":"10 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.D.C.: \u201cad hoc\u201d medical monitor for Medica Scientia Innovation Research (MEDSIR), Barcelona (Spain); support for attending meetings and\/or travel from Daiichi Sankyo, and participation in an advisory board for Pfizer; institutional European grant PNRR-POC-2023-12378113 project, founded by the European Union - Next Generation EU - PNRR M6C2. G.A. declared no competing financial or non financial interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"93"}}